Allogene Therapeutics Inc. logo

Allogene Therapeutics Inc.

ALLO | NASDAQ
Chart Builder DCF Calculator
$1.71
+$0.02 (+1.18%)
At close: Sep 22, 2026, 4:00 PM ET
$1.74
+$0.03 (+1.71%)
After-hours: Sep 22, 2026, 7:54 PM ET

Market Data

Market Cap
$583.31M
Enterprise Value
$321.06M
Beta
0.48
Average Volume
7.22M
Shares Outstanding (Diluted)
328.93M
Shares Change YoY
50.24%
Institutional Ownership
76.65%
Exchange
NASDAQ
ISIN
US0197701065

Price Performance

Price Change 1M
-19.9%
Price Change 3M
-18.4%
Price Change 6M
-27.5%
Price Change YTD
25.2%
Price Change 1Y
44.4%
Price Change 3Y
-53.7%
Price Change 5Y
-93.4%
1M CAGR (ann.)
-15.9%
1Y CAGR (ann.)
39.7%
5Y CAGR (ann.)
-41.5%
All-Time CAGR
-28.7%

Valuation

PE Ratio
-2.52
Forward PE
N/A
PEG Ratio
-0.04
Forward PEG
-0.44
PS Ratio
125.71
Forward PS
43.40
PB Ratio
1.34
P/FCF Ratio
-5.69
P/Adj. FCF Ratio
-4.16
P/OCF Ratio
-5.45
EV/Sales
69.19
EV/EBIT
-1.96
EV/EBITDA
-2.10
EV/FCF
-3.13
Earnings Yield
-39.6%
FCF Yield
-17.6%
Adj. FCF Yield
-24.0%

Financial Health

Net Cash
$332.6M
Total Debt
$70.35M
Cash & Short-Term Investments
$332.6M
Total Assets
$550.09M
Current Ratio
10.72
Quick Ratio
10.72
Debt / Equity Ratio
0.16
Debt / EBITDA
-0.46
Debt / FCF
-0.69
OCF / Debt
-1.45
Interest Coverage
-138.71
Altman Z-Score
-2.57
Piotroski F-Score
4

Margins & Profitability

Gross Profit Margin
-699.4%
Operating Profit Margin
-3886.1%
EBITDA Margin
-3287.2%
Net Profit Margin
-3566.7%
FCF Margin
-2211.2%
Adj. FCF Margin
-3019.2%
SBC / Revenue
808.0%
SBC Impact (per share)
-36.5%

Returns

Return on Assets
-30.1%
Return on Equity
-50.0%
Return on Invested Capital
-34.8%
Return on Capital Employed
-34.8%
Return on Tangible Assets
-30.1%

Historical Growth (CAGR)

Revenue CAGR 3Y
215.3%
Revenue CAGR 5Y
-34.5%
Revenue CAGR 10Y
N/A
EPS CAGR 3Y
41.6%
EPS CAGR 5Y
27.3%
EPS CAGR 10Y
N/A
FCF CAGR 3Y
37.5%
FCF CAGR 5Y
15.0%
FCF CAGR 10Y
N/A

Analyst Forecasts

Analyst Rating
Buy
Analyst Count
30
EPS Growth Next 3Y
N/A
Revenue Growth Next 3Y
323.0%
Earnings Date
Nov 4, 2026
EPS Estimate (next Q)
-$0.13
EPS Growth Est (next Q)
-31.6%
Revenue Est (next Q)
$2.5K
Revenue Growth Est (next Q)
N/A

Fair Value Estimates

Graham Number
N/A
Graham Upside
N/A
Lynch Fair Value
N/A
Lynch Upside
N/A
Price Target
$6.43
Price Target Upside
280.5%

Cash Flow

Operating Cash Flow
$-102.2M
Free Cash Flow
$-102.6M
Adj. Free Cash Flow
$-140.09M
FCF Per Share
-$0.31
OCF Per Share
-$0.31
OCF/S Ratio
-2202.5%

Income Statement

Revenue
$4.64M
Gross Profit
$-32.45M
Operating Income
$-180.32M
EBITDA
$-152.53M
Net Income
$-165.49M
EPS (Diluted)
-$0.67
Revenue / Employee
$30.73K
Profit / Employee
$-1.1M
Employees
151

© 2026 bestshares.com. All rights reserved.